Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen

Kim, Seong Hwan; Lee, Miri; Lee, Keun-Cheol; Lee, Jinhwa; Kwon, Hyuk‐Chan; Kim, Dae‐Cheol; Lee, Kyeong Woo; Cho, Se-Heon

doi:10.4048/jbc.2010.13.4.325

Cited by 2 publications

(6 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the research-focused implementation phase of our study, it was found that 37 % (10/27) of breast cancer patients from the implementation data set suffers from depression, while the use of antidepressants for depression were documented in four patients (15 %). These findings are in agreement with previous studies which reported that between 20 % and 30 % of TAM-treated breast cancer patients also use antidepressants (Nelson et al 2006 ; Kim et al 2010 ).…”

Section: Discussionsupporting

confidence: 94%

“…These include frequent use of antidepressants prescribed to treat depression in breast cancer patients and/or menopausal vasomotor symptoms such as hot flashes. TAM treatment may induce or aggravate depression or anxiety, and commonly causes hot flashes (Kim et al 2010 ). During the research-focused implementation phase of our study, it was found that 37 % (10/27) of breast cancer patients from the implementation data set suffers from depression, while the use of antidepressants for depression were documented in four patients (15 %).…”

Section: Discussionmentioning

confidence: 99%

“…TAM is the standard 5 year endocrine treatment for premenopausal and postmenopausal women with ER-positive breast cancer. In contrast, aromatase inhibitors are frequently prescribed for postmenopausal women (Kim et al 2010 ). The use of aromatase inhibitors has been prohibited in premenopausal breast cancer patients due to the activation of ovarian functions implicated in polycystic ovarian diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Depression is the most common psychiatric problem in cancer patients. As the age at diagnosis of breast cancer decreases in the general population, the risk of depression becomes higher (Kim et al 2010 ). Younger patients suffer more from psychiatric distress, resulting in negative effects on quality of life and survival rate.…”

Section: Introductionmentioning

confidence: 99%

“…The treatment of depression as part of a comprehensive risk reduction approach is therefore an important consideration in patients with breast cancer. It has been reported that between 20 % and 30 % of breast cancer patients treated with Tamoxifen (TAM) to reduce recurrence risk, also use antidepressants for depression or hot flashes (Nelson et al 2006 ; Kim et al 2010 ).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application

Merwe

Bouwens

Pienaar³

et al. 2012

Metab Brain Dis

View full text Add to dashboard Cite

Approximately 25 % of clinically important drugs and numerous environmental carcinogens are metabolised by CYP2D6. Variation in the CYP2D6 gene and concomitant use of tamoxifen (TAM) with certain antidepressants may increase recurrence risk in breast cancer patients due to reduced enzyme activity. In this study we determined the appropriateness of adding CYP2D6 genotyping to the breast cancer genetic testing options already available in South Africa, which include BRCA mutation screening and transcriptional profiling to assess estrogen receptor (ER) status. A total of 114 South African breast cancer patients, including 52 Caucasian and 62 Coloured (Mixed ancestry), and 63 Caucasian control individuals were genotyped for the most common inactivating allele (CYP2D6*4, rs3892097) previously identified in the CYP2D6 gene. In the initial validation data set consisting of 25 Caucasian and 62 Coloured patients, the CYP2D6*4 allele frequency was significantly higher in Caucasian compared to Coloured patients (24 % vs. 3 %, p < 0.001), similar to previous findings in the general South African population. Extended CYP2D6 genotyping was subsequently performed in an implementation data set of 27 Caucasian breast cancer patients, to determine the prevalence of depression and use of antidepressants in a clinical setting. A medical history of depression and/or use of antidepressants was reported in 37 % (10/27) of these breast cancer patients genotyped for CYP2D6*4. This translational research study has led to increased awareness among clinicians of the potential benefits of CYP2D6 genotyping to facilitate prevention of cumulative risk in a high-risk genetic subgroup of breast cancer patients considered for concomitant treatment of TAM and antidepressants that may reduce enzyme function.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations